The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.
 
Jacob Drobnyk Soumerai
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb; TG Therapeutics
Research Funding - Adaptive Biotechnologies; BeiGene; BostonGene; Genentech/Roche; GlaxoSmithKline; TG Therapeutics
 
Deepa Jagadeesh
Consulting or Advisory Role - Atara Biotherapeutics; Kyowa Hakko Kirin; Verastem
Speakers' Bureau - Verastem
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Debiopharm Group (Inst); MEI Pharma (Inst); MEI Pharma (Inst); Regeneron (Inst); Rhizen Pharmaceuticals (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Huda S. Salman
No Relationships to Disclose
 
Izidore S. Lossos
Honoraria - Janssen Biotech
Consulting or Advisory Role - Janssen Scientific Affairs; Seagen; Verastem
Research Funding - NCI
Patents, Royalties, Other Intellectual Property - Stanford- Royalties
 
Adam Steven Asch
Research Funding - Astellas Pharma (Inst); Cartesian Therapeutics (Inst); Forty Seven (Inst); Juno Therapeutics (Inst); Macrogenics (Inst); MEI Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Provisional patent submitted (I)
 
Nishitha Reddy
Honoraria - Celgene; Morphosys
 
Vaishalee Padgaonkar Kenkre
No Relationships to Disclose
 
John M. Pagel
Consulting or Advisory Role - Actinium Pharmaceuticals; AstraZeneca; BeiGene; Epizyme; Gilead Sciences; Loxo; MEI Pharma; MorphoSys; TG Therapeutics
 
Daniel O Persky
Consulting or Advisory Role - Bayer; Celgene; Cellectar; Debiopharm Group; Epizyme; Karyopharm Therapeutics; kymera; MorphoSys
Research Funding - Merck (Inst)
 
Farrukh Tauseef Awan
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Celgene; Clinical Care Options; DAVA Pharmaceuticals; Genentech; Gilead Sciences; Janssen Oncology; Karyopharm Therapeutics; Medscape; MEI Pharma; Novartis; Pharmacyclics; Sunesis Pharmaceuticals; Verastem
Speakers' Bureau - Abbvie; AstraZeneca
Research Funding - Innate Pharma; Pharmacyclics
 
Catherine S. Magid Diefenbach
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Genentech/Roche; Janssen; Merck; MorphoSys; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); LAM Therapeutics (Inst); MEI Pharma (Inst); Merck (Inst); Millennium (Inst); Roche/Genentech (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Wenying Huang
Employment - MEI Pharma
Consulting or Advisory Role - Amgen
 
Judith Llorin-Sangalang
Employment - MEI Pharma
Research Funding - MEI Pharma
Travel, Accommodations, Expenses - MEI Pharma
 
Igor Gorbatchevsky
Employment - Bayer; Iovance Biotherapeutics; MEI Pharma
 
Andrew David Zelenetz
Honoraria - Clinical Care Options; NCCN; Oncology Information Group; PER; Plexus
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Celgene; Coherus Biosciences; Curio Science; Curis; Dava Oncology; Debiopharm Group; Genentech/Roche; Gilead Sciences; Juno/Celgene/Bristol-Myers Squibb; Karyopharm Therapeutics; Kite, a Gilead company; MEI Pharma; MorphoSys; Pharmacyclics; Quant Health; Seagen; Vaniam Group; Verastem
Research Funding - BeiGene; Genentech/Roche; Gilead Sciences; MEI Pharma